Look up one drug

Exceptional Access criteria on record are for Brand(s): Xtandi; DOSAGE FORM/ STRENGTH: 40 mg capsule — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Updated: December 1, 2021 Initiation criteria for metastatic castration sensitive prostate cancer (mCSPC): For the treatment metastatic castration sensitive prostate cancer (mCSPC) in patients who meet all of the following criteria: 1. Enzalutamide is used in combination with androgen deprivation therapy (ADT)1; AND 2. Metastatic lesions detected on technetium-99m bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI); AND 3. Castration sensitive as defined by the patient being treatment naïve to an ADT OR ADT initiated within the prior 6 months before start of therapy with enzalutamide OR ADT used in the neoadjuvant or adjuvant setting where the patient has been off treatment for 12 months or more prior to start of enzalutamide; AND 4. Has not experienced disease progression with another an androgen receptor axis targeted therapy (ARAT) for castration sensitive prostate cancer; AND 5. Patient has good performance status. 1ADT is not required for patients with bilateral orchiectomy Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) ARAT- An androgen receptor axis targeted therapy (e.g. abiraterone, apalutamide, darolutamide, enzalutamide) The following baseline levels are to be provided with the initial application; i) Number of metastatic lesions on bone scan and in soft tissues ii) Testosterone level iii) Baseline (pre-treatment) PSA level iv) Pre-treatment Gleason score (optional) 305 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Notes: 1. Patients who have previously progressed on a second-generation androgen receptor inhibitor (e.g. apalutamide, enzalutamide, darolutamide) for prostate cancer will not be eligible for enzalutamide in mCSPC. The Ministry will fund only one of enzalutamide or apalutamide in patients with mCSPC. 2. Patients treated with apalutamide or darolutamide as part of a clinical trial may be eligible for enzalutamide and will be considered on a case-by-case basis. 3. Patients who progress on treatment with enzalutamide or apalutamide mCSPC will not be eligible for enzalutamide in the metastatic castration resistant setting. 4. Patients who are currently on a treatment regimen with an androgen receptor axis targeted therapy (e.g. abiraterone or a second-generation androgen receptor inhibitor) for prostate cancer, must meet the initiation criteria if they wish to switch to publicly funded enzalutamide for mCSPC. 5. Time limited funding consideration will be provided on a case-by case basis for those patients who are using docetaxel in combination with ADT as long as there has been no progression and the treatment regimen has not been used for more than 6 months. Approved Dosage: 160 mg administered orally once daily. Renewal Criteria: Renewals will be considered in patients until disease progression (i.e. PSA elevation in addition to radiographic disease progression, or PSA progression in addition to clinical symptoms associated with cancer progression), development of castration resistant disease, or experiencing unacceptable toxicity while on enzalutamide. Exclusion Criteria: (Patients meeting any of the following will not be funded.) 1. Patients who have previously experienced disease progression on enzalutamide or another ARI used in the setting of prostate cancer. 2. Patients who have risk factors for seizures 3. Enzalutamide will not be funded as combination therapy with another androgen receptor axis targeted therapy. Approved Dosage for Initials and Renewals:160 mg administered orally once daily. Duration of initial and renewal approvals: 1 year 306 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Initiation Criteria for high risk non-metastatic castration resistant prostate cancer (nmCRPC): For the treatment of high risk non-metastatic castration resistant prostate cancer (nmCRPC) in patients who meet all the following criteria: 1. Patient using Xtandi in combination with androgen deprivation therapy (ADT); AND 2. Has no detectable distant metastases as determined by CT, MRI, or technetium-99m bone scan; AND 3. Patient has castration resistant disease based on meeting all the following indicia observed while on continuous ADT treatment or post orchiectomy: • Castrate serum testosterone levels: AND • Biochemical progression defined as Three (3) prostate-specific antigen (PSA) rises at least 1 week apart, with the last PSA greater than 2ng/mL; and 4. Patient is at high risk for developing metastatic disease based on a Prostate-specific antigen doubling time (PSADT) of less than or equal to 10 months during continuous ADT. 5. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2. Approval Duration: 1 year Exclusion Criteria: 1. The patient received prior chemotherapy for the treatment of prostate cancer, unless it was in the adjuvant or neoadjuvant setting. 2. The patient has previously experienced disease progression on apalutamide or darolutamide used for prostate cancer. 3. The patient has risk factors for seizures. 307 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) Approved Dosage: 160mg administered orally once daily Notes: 1. The Ministry will fund only one second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, or enzalutamide) in patients with nmCRPC. 2. Patients who have progressed on enzalutamide in nmCRPC will not be eligible for enzalutamide in metastatic castration resistant prostate cancer (mCRPC). 3. Requests for enzalutamide in patients who have initiated another ARI therapy in the nmCRPC setting and who have not experienced disease progression will be considered on a case-by-case basis. Renewal Criteria: Renewals will be considered in patients without evidence of radiographic disease progression or unacceptable toxicity while on enzalutamide therapy. Approval Duration: 1 year 308 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Initiation criteria for metastatic castration resistant prostate cancer (mCRPC): For the treatment of metastatic castration resistant prostate cancer (mCRPC) in patients meeting the following criteria: 1. Enzalutamide is used in combination with androgen deprivation therapy (ADT)1; AND 2. Metastatic lesions detected on a bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI); AND 3. Patient has castration resistant disease based on meeting the following indicia observed while on continuous ADT treatment or post orchiectomy: 4. Castrate serum testosterone levels; AND 5. Biochemical progression defined as three (3) prostate-specific antigen (PSA) rises at least 1 week apart, with the last PSA greater than 2ng/mL AND/OR radiographic progression of new or pre-existing disease as determined by the detection of 2 or more lesions on bone scan or presence of new soft tissue lesions by RECIST criteria; AND 6. Patient has progressed on a docetaxel-based chemotherapy OR Patient is using enzalutamide pre-docetaxel for metastatic castration resistant prostate cancer and has not previously experienced disease progression on enzalutamide or another second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide,) used for prostate cancer OR Patient is using enzalutamide pre-docetaxel for mCRPC and has not previously experienced disease progression on abiraterone used in mCRPC sequenced immediately prior to enzalutamide; AND 7. Patient has good performance status defined as an Eastern Cooperative Oncology Group (ECOG) Performance status less than or equal to 2. 1ADT is not required for patients with bilateral orchiectomy Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) ARAT- An androgen receptor axis targeted therapy (e.g. abiraterone, apalutamide, darolutamide, enzalutamide) 309 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Notes: 1. Patients who have progressed on treatment with second generation androgen receptor inhibitors (e.g. apalutamide, enzalutamide, darolutamide) used in prior stages of prostate cancer will not be eligible for enzalutamide in the metastatic castration resistant setting. 2. Patients treated with apalutamide or darolutamide as part of a clinical trial may be eligible for enzalutamide and will be considered on a case-by-case basis. 3. Requests for enzalutamide in patients who initiated abiraterone therapy and who have not had disease progression while on abiraterone will be considered on a case-by- case basis. Exclusion criteria: (Patients meeting any of the following will not be funded) 1. The patient has risk factors for seizures; 2. Enzalutamide will not be funded as combination therapy with another androgen receptor axis targeted therapy or cabazitaxel. Renewals: Renewals will be considered in patients who have not experienced disease progression while on enzalutamide therapy. Approved Dosage for Initials and Renewals:160 mg administered orally once daily. Duration of initial and renewal approvals: 1 year 310  EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 305, record 183, corpus 2025-01-01; name match only, not an eligibility decision

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Apo-Enzalutamide · DIN 02562677 Manufacturer: Apotex Inc.; listing date 2026-05-29 Health Canada: Marketed since 2026-03-30 · brand APO-ENZALUTAMIDE · ATC L02BB04 ENZALUTAMIDE · form Capsule · route Oral · ingredients ENZALUTAMIDE 40 MG · company Apotex inc · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02562677). DIN 02562677: Apo-Enzalutamide Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 100000224; group id 156; item number 0267; lccId None; manufacturer id APX Source form: Cap; strength: 40mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $7.2989; ministry $7.2989 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02562677 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106553

Interchangeable products

Auro-Enzalutamide · DIN 02494736 · $7.2989 Jamp Enzalutamide · DIN 02515229 · $7.2989 Reddy-Enzalutamide · DIN 02558424 · $7.2989 Xtandi · DIN 02407329 · $7.2989

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02562677

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Exceptional Access criteria on record are for Brand(s): Xtandi; DOSAGE FORM/ STRENGTH: 40 mg capsule — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Updated: December 1, 2021 Initiation criteria for metastatic castration sensitive prostate cancer (mCSPC): For the treatment metastatic castration sensitive prostate cancer (mCSPC) in patients who meet all of the following criteria: 1. Enzalutamide is used in combination with androgen deprivation therapy (ADT)1; AND 2. Metastatic lesions detected on technetium-99m bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI); AND 3. Castration sensitive as defined by the patient being treatment naïve to an ADT OR ADT initiated within the prior 6 months before start of therapy with enzalutamide OR ADT used in the neoadjuvant or adjuvant setting where the patient has been off treatment for 12 months or more prior to start of enzalutamide; AND 4. Has not experienced disease progression with another an androgen receptor axis targeted therapy (ARAT) for castration sensitive prostate cancer; AND 5. Patient has good performance status. 1ADT is not required for patients with bilateral orchiectomy Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) ARAT- An androgen receptor axis targeted therapy (e.g. abiraterone, apalutamide, darolutamide, enzalutamide) The following baseline levels are to be provided with the initial application; i) Number of metastatic lesions on bone scan and in soft tissues ii) Testosterone level iii) Baseline (pre-treatment) PSA level iv) Pre-treatment Gleason score (optional) 305 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Notes: 1. Patients who have previously progressed on a second-generation androgen receptor inhibitor (e.g. apalutamide, enzalutamide, darolutamide) for prostate cancer will not be eligible for enzalutamide in mCSPC. The Ministry will fund only one of enzalutamide or apalutamide in patients with mCSPC. 2. Patients treated with apalutamide or darolutamide as part of a clinical trial may be eligible for enzalutamide and will be considered on a case-by-case basis. 3. Patients who progress on treatment with enzalutamide or apalutamide mCSPC will not be eligible for enzalutamide in the metastatic castration resistant setting. 4. Patients who are currently on a treatment regimen with an androgen receptor axis targeted therapy (e.g. abiraterone or a second-generation androgen receptor inhibitor) for prostate cancer, must meet the initiation criteria if they wish to switch to publicly funded enzalutamide for mCSPC. 5. Time limited funding consideration will be provided on a case-by case basis for those patients who are using docetaxel in combination with ADT as long as there has been no progression and the treatment regimen has not been used for more than 6 months. Approved Dosage: 160 mg administered orally once daily. Renewal Criteria: Renewals will be considered in patients until disease progression (i.e. PSA elevation in addition to radiographic disease progression, or PSA progression in addition to clinical symptoms associated with cancer progression), development of castration resistant disease, or experiencing unacceptable toxicity while on enzalutamide. Exclusion Criteria: (Patients meeting any of the following will not be funded.) 1. Patients who have previously experienced disease progression on enzalutamide or another ARI used in the setting of prostate cancer. 2. Patients who have risk factors for seizures 3. Enzalutamide will not be funded as combination therapy with another androgen receptor axis targeted therapy. Approved Dosage for Initials and Renewals:160 mg administered orally once daily. Duration of initial and renewal approvals: 1 year 306 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Initiation Criteria for high risk non-metastatic castration resistant prostate cancer (nmCRPC): For the treatment of high risk non-metastatic castration resistant prostate cancer (nmCRPC) in patients who meet all the following criteria: 1. Patient using Xtandi in combination with androgen deprivation therapy (ADT); AND 2. Has no detectable distant metastases as determined by CT, MRI, or technetium-99m bone scan; AND 3. Patient has castration resistant disease based on meeting all the following indicia observed while on continuous ADT treatment or post orchiectomy: • Castrate serum testosterone levels: AND • Biochemical progression defined as Three (3) prostate-specific antigen (PSA) rises at least 1 week apart, with the last PSA greater than 2ng/mL; and 4. Patient is at high risk for developing metastatic disease based on a Prostate-specific antigen doubling time (PSADT) of less than or equal to 10 months during continuous ADT. 5. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2. Approval Duration: 1 year Exclusion Criteria: 1. The patient received prior chemotherapy for the treatment of prostate cancer, unless it was in the adjuvant or neoadjuvant setting. 2. The patient has previously experienced disease progression on apalutamide or darolutamide used for prostate cancer. 3. The patient has risk factors for seizures. 307 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) Approved Dosage: 160mg administered orally once daily Notes: 1. The Ministry will fund only one second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, or enzalutamide) in patients with nmCRPC. 2. Patients who have progressed on enzalutamide in nmCRPC will not be eligible for enzalutamide in metastatic castration resistant prostate cancer (mCRPC). 3. Requests for enzalutamide in patients who have initiated another ARI therapy in the nmCRPC setting and who have not experienced disease progression will be considered on a case-by-case basis. Renewal Criteria: Renewals will be considered in patients without evidence of radiographic disease progression or unacceptable toxicity while on enzalutamide therapy. Approval Duration: 1 year 308 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Initiation criteria for metastatic castration resistant prostate cancer (mCRPC): For the treatment of metastatic castration resistant prostate cancer (mCRPC) in patients meeting the following criteria: 1. Enzalutamide is used in combination with androgen deprivation therapy (ADT)1; AND 2. Metastatic lesions detected on a bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI); AND 3. Patient has castration resistant disease based on meeting the following indicia observed while on continuous ADT treatment or post orchiectomy: 4. Castrate serum testosterone levels; AND 5. Biochemical progression defined as three (3) prostate-specific antigen (PSA) rises at least 1 week apart, with the last PSA greater than 2ng/mL AND/OR radiographic progression of new or pre-existing disease as determined by the detection of 2 or more lesions on bone scan or presence of new soft tissue lesions by RECIST criteria; AND 6. Patient has progressed on a docetaxel-based chemotherapy OR Patient is using enzalutamide pre-docetaxel for metastatic castration resistant prostate cancer and has not previously experienced disease progression on enzalutamide or another second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide,) used for prostate cancer OR Patient is using enzalutamide pre-docetaxel for mCRPC and has not previously experienced disease progression on abiraterone used in mCRPC sequenced immediately prior to enzalutamide; AND 7. Patient has good performance status defined as an Eastern Cooperative Oncology Group (ECOG) Performance status less than or equal to 2. 1ADT is not required for patients with bilateral orchiectomy Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) ARAT- An androgen receptor axis targeted therapy (e.g. abiraterone, apalutamide, darolutamide, enzalutamide) 309 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Notes: 1. Patients who have progressed on treatment with second generation androgen receptor inhibitors (e.g. apalutamide, enzalutamide, darolutamide) used in prior stages of prostate cancer will not be eligible for enzalutamide in the metastatic castration resistant setting. 2. Patients treated with apalutamide or darolutamide as part of a clinical trial may be eligible for enzalutamide and will be considered on a case-by-case basis. 3. Requests for enzalutamide in patients who initiated abiraterone therapy and who have not had disease progression while on abiraterone will be considered on a case-by- case basis. Exclusion criteria: (Patients meeting any of the following will not be funded) 1. The patient has risk factors for seizures; 2. Enzalutamide will not be funded as combination therapy with another androgen receptor axis targeted therapy or cabazitaxel. Renewals: Renewals will be considered in patients who have not experienced disease progression while on enzalutamide therapy. Approved Dosage for Initials and Renewals:160 mg administered orally once daily. Duration of initial and renewal approvals: 1 year 310  EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 305, record 183, corpus 2025-01-01; name match only, not an eligibility decision

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Auro-Enzalutamide · DIN 02494736 Manufacturer: Auro Pharma Inc.; listing date 2026-05-29 Health Canada: Marketed since 2026-03-30 · brand AURO-ENZALUTAMIDE · ATC L02BB04 ENZALUTAMIDE · form Capsule · route Oral · ingredients ENZALUTAMIDE 40 MG · company Auro pharma inc · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02494736). DIN 02494736: Auro-Enzalutamide Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 100000224; group id 156; item number 0267; lccId None; manufacturer id AUR Source form: Cap; strength: 40mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $7.2989; ministry $7.2989 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02494736 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98471

Interchangeable products

Apo-Enzalutamide · DIN 02562677 · $7.2989 Jamp Enzalutamide · DIN 02515229 · $7.2989 Reddy-Enzalutamide · DIN 02558424 · $7.2989 Xtandi · DIN 02407329 · $7.2989

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02494736

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Exceptional Access criteria on record are for Brand(s): Xtandi; DOSAGE FORM/ STRENGTH: 40 mg capsule — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Updated: December 1, 2021 Initiation criteria for metastatic castration sensitive prostate cancer (mCSPC): For the treatment metastatic castration sensitive prostate cancer (mCSPC) in patients who meet all of the following criteria: 1. Enzalutamide is used in combination with androgen deprivation therapy (ADT)1; AND 2. Metastatic lesions detected on technetium-99m bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI); AND 3. Castration sensitive as defined by the patient being treatment naïve to an ADT OR ADT initiated within the prior 6 months before start of therapy with enzalutamide OR ADT used in the neoadjuvant or adjuvant setting where the patient has been off treatment for 12 months or more prior to start of enzalutamide; AND 4. Has not experienced disease progression with another an androgen receptor axis targeted therapy (ARAT) for castration sensitive prostate cancer; AND 5. Patient has good performance status. 1ADT is not required for patients with bilateral orchiectomy Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) ARAT- An androgen receptor axis targeted therapy (e.g. abiraterone, apalutamide, darolutamide, enzalutamide) The following baseline levels are to be provided with the initial application; i) Number of metastatic lesions on bone scan and in soft tissues ii) Testosterone level iii) Baseline (pre-treatment) PSA level iv) Pre-treatment Gleason score (optional) 305 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Notes: 1. Patients who have previously progressed on a second-generation androgen receptor inhibitor (e.g. apalutamide, enzalutamide, darolutamide) for prostate cancer will not be eligible for enzalutamide in mCSPC. The Ministry will fund only one of enzalutamide or apalutamide in patients with mCSPC. 2. Patients treated with apalutamide or darolutamide as part of a clinical trial may be eligible for enzalutamide and will be considered on a case-by-case basis. 3. Patients who progress on treatment with enzalutamide or apalutamide mCSPC will not be eligible for enzalutamide in the metastatic castration resistant setting. 4. Patients who are currently on a treatment regimen with an androgen receptor axis targeted therapy (e.g. abiraterone or a second-generation androgen receptor inhibitor) for prostate cancer, must meet the initiation criteria if they wish to switch to publicly funded enzalutamide for mCSPC. 5. Time limited funding consideration will be provided on a case-by case basis for those patients who are using docetaxel in combination with ADT as long as there has been no progression and the treatment regimen has not been used for more than 6 months. Approved Dosage: 160 mg administered orally once daily. Renewal Criteria: Renewals will be considered in patients until disease progression (i.e. PSA elevation in addition to radiographic disease progression, or PSA progression in addition to clinical symptoms associated with cancer progression), development of castration resistant disease, or experiencing unacceptable toxicity while on enzalutamide. Exclusion Criteria: (Patients meeting any of the following will not be funded.) 1. Patients who have previously experienced disease progression on enzalutamide or another ARI used in the setting of prostate cancer. 2. Patients who have risk factors for seizures 3. Enzalutamide will not be funded as combination therapy with another androgen receptor axis targeted therapy. Approved Dosage for Initials and Renewals:160 mg administered orally once daily. Duration of initial and renewal approvals: 1 year 306 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Initiation Criteria for high risk non-metastatic castration resistant prostate cancer (nmCRPC): For the treatment of high risk non-metastatic castration resistant prostate cancer (nmCRPC) in patients who meet all the following criteria: 1. Patient using Xtandi in combination with androgen deprivation therapy (ADT); AND 2. Has no detectable distant metastases as determined by CT, MRI, or technetium-99m bone scan; AND 3. Patient has castration resistant disease based on meeting all the following indicia observed while on continuous ADT treatment or post orchiectomy: • Castrate serum testosterone levels: AND • Biochemical progression defined as Three (3) prostate-specific antigen (PSA) rises at least 1 week apart, with the last PSA greater than 2ng/mL; and 4. Patient is at high risk for developing metastatic disease based on a Prostate-specific antigen doubling time (PSADT) of less than or equal to 10 months during continuous ADT. 5. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2. Approval Duration: 1 year Exclusion Criteria: 1. The patient received prior chemotherapy for the treatment of prostate cancer, unless it was in the adjuvant or neoadjuvant setting. 2. The patient has previously experienced disease progression on apalutamide or darolutamide used for prostate cancer. 3. The patient has risk factors for seizures. 307 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) Approved Dosage: 160mg administered orally once daily Notes: 1. The Ministry will fund only one second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, or enzalutamide) in patients with nmCRPC. 2. Patients who have progressed on enzalutamide in nmCRPC will not be eligible for enzalutamide in metastatic castration resistant prostate cancer (mCRPC). 3. Requests for enzalutamide in patients who have initiated another ARI therapy in the nmCRPC setting and who have not experienced disease progression will be considered on a case-by-case basis. Renewal Criteria: Renewals will be considered in patients without evidence of radiographic disease progression or unacceptable toxicity while on enzalutamide therapy. Approval Duration: 1 year 308 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Initiation criteria for metastatic castration resistant prostate cancer (mCRPC): For the treatment of metastatic castration resistant prostate cancer (mCRPC) in patients meeting the following criteria: 1. Enzalutamide is used in combination with androgen deprivation therapy (ADT)1; AND 2. Metastatic lesions detected on a bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI); AND 3. Patient has castration resistant disease based on meeting the following indicia observed while on continuous ADT treatment or post orchiectomy: 4. Castrate serum testosterone levels; AND 5. Biochemical progression defined as three (3) prostate-specific antigen (PSA) rises at least 1 week apart, with the last PSA greater than 2ng/mL AND/OR radiographic progression of new or pre-existing disease as determined by the detection of 2 or more lesions on bone scan or presence of new soft tissue lesions by RECIST criteria; AND 6. Patient has progressed on a docetaxel-based chemotherapy OR Patient is using enzalutamide pre-docetaxel for metastatic castration resistant prostate cancer and has not previously experienced disease progression on enzalutamide or another second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide,) used for prostate cancer OR Patient is using enzalutamide pre-docetaxel for mCRPC and has not previously experienced disease progression on abiraterone used in mCRPC sequenced immediately prior to enzalutamide; AND 7. Patient has good performance status defined as an Eastern Cooperative Oncology Group (ECOG) Performance status less than or equal to 2. 1ADT is not required for patients with bilateral orchiectomy Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) ARAT- An androgen receptor axis targeted therapy (e.g. abiraterone, apalutamide, darolutamide, enzalutamide) 309 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Notes: 1. Patients who have progressed on treatment with second generation androgen receptor inhibitors (e.g. apalutamide, enzalutamide, darolutamide) used in prior stages of prostate cancer will not be eligible for enzalutamide in the metastatic castration resistant setting. 2. Patients treated with apalutamide or darolutamide as part of a clinical trial may be eligible for enzalutamide and will be considered on a case-by-case basis. 3. Requests for enzalutamide in patients who initiated abiraterone therapy and who have not had disease progression while on abiraterone will be considered on a case-by- case basis. Exclusion criteria: (Patients meeting any of the following will not be funded) 1. The patient has risk factors for seizures; 2. Enzalutamide will not be funded as combination therapy with another androgen receptor axis targeted therapy or cabazitaxel. Renewals: Renewals will be considered in patients who have not experienced disease progression while on enzalutamide therapy. Approved Dosage for Initials and Renewals:160 mg administered orally once daily. Duration of initial and renewal approvals: 1 year 310  EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 305, record 183, corpus 2025-01-01; name match only, not an eligibility decision

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Jamp Enzalutamide · DIN 02515229 Manufacturer: Jamp Pharma Corporation; listing date 2026-03-31 Health Canada: Marketed since 2026-02-20 · brand JAMP ENZALUTAMIDE · ATC L02BB04 ENZALUTAMIDE · form Capsule · route Oral · ingredients ENZALUTAMIDE 40 MG · company Jamp pharma corporation · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02515229). DIN 02515229: Jamp Enzalutamide Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 100000224; group id 156; item number 0267; lccId None; manufacturer id JPC Source form: Cap; strength: 40mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $7.2989; ministry $7.2989 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02515229 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100461

Interchangeable products

Apo-Enzalutamide · DIN 02562677 · $7.2989 Auro-Enzalutamide · DIN 02494736 · $7.2989 Reddy-Enzalutamide · DIN 02558424 · $7.2989 Xtandi · DIN 02407329 · $7.2989

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02515229

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Exceptional Access criteria on record are for Brand(s): Xtandi; DOSAGE FORM/ STRENGTH: 40 mg capsule — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Updated: December 1, 2021 Initiation criteria for metastatic castration sensitive prostate cancer (mCSPC): For the treatment metastatic castration sensitive prostate cancer (mCSPC) in patients who meet all of the following criteria: 1. Enzalutamide is used in combination with androgen deprivation therapy (ADT)1; AND 2. Metastatic lesions detected on technetium-99m bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI); AND 3. Castration sensitive as defined by the patient being treatment naïve to an ADT OR ADT initiated within the prior 6 months before start of therapy with enzalutamide OR ADT used in the neoadjuvant or adjuvant setting where the patient has been off treatment for 12 months or more prior to start of enzalutamide; AND 4. Has not experienced disease progression with another an androgen receptor axis targeted therapy (ARAT) for castration sensitive prostate cancer; AND 5. Patient has good performance status. 1ADT is not required for patients with bilateral orchiectomy Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) ARAT- An androgen receptor axis targeted therapy (e.g. abiraterone, apalutamide, darolutamide, enzalutamide) The following baseline levels are to be provided with the initial application; i) Number of metastatic lesions on bone scan and in soft tissues ii) Testosterone level iii) Baseline (pre-treatment) PSA level iv) Pre-treatment Gleason score (optional) 305 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Notes: 1. Patients who have previously progressed on a second-generation androgen receptor inhibitor (e.g. apalutamide, enzalutamide, darolutamide) for prostate cancer will not be eligible for enzalutamide in mCSPC. The Ministry will fund only one of enzalutamide or apalutamide in patients with mCSPC. 2. Patients treated with apalutamide or darolutamide as part of a clinical trial may be eligible for enzalutamide and will be considered on a case-by-case basis. 3. Patients who progress on treatment with enzalutamide or apalutamide mCSPC will not be eligible for enzalutamide in the metastatic castration resistant setting. 4. Patients who are currently on a treatment regimen with an androgen receptor axis targeted therapy (e.g. abiraterone or a second-generation androgen receptor inhibitor) for prostate cancer, must meet the initiation criteria if they wish to switch to publicly funded enzalutamide for mCSPC. 5. Time limited funding consideration will be provided on a case-by case basis for those patients who are using docetaxel in combination with ADT as long as there has been no progression and the treatment regimen has not been used for more than 6 months. Approved Dosage: 160 mg administered orally once daily. Renewal Criteria: Renewals will be considered in patients until disease progression (i.e. PSA elevation in addition to radiographic disease progression, or PSA progression in addition to clinical symptoms associated with cancer progression), development of castration resistant disease, or experiencing unacceptable toxicity while on enzalutamide. Exclusion Criteria: (Patients meeting any of the following will not be funded.) 1. Patients who have previously experienced disease progression on enzalutamide or another ARI used in the setting of prostate cancer. 2. Patients who have risk factors for seizures 3. Enzalutamide will not be funded as combination therapy with another androgen receptor axis targeted therapy. Approved Dosage for Initials and Renewals:160 mg administered orally once daily. Duration of initial and renewal approvals: 1 year 306 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Initiation Criteria for high risk non-metastatic castration resistant prostate cancer (nmCRPC): For the treatment of high risk non-metastatic castration resistant prostate cancer (nmCRPC) in patients who meet all the following criteria: 1. Patient using Xtandi in combination with androgen deprivation therapy (ADT); AND 2. Has no detectable distant metastases as determined by CT, MRI, or technetium-99m bone scan; AND 3. Patient has castration resistant disease based on meeting all the following indicia observed while on continuous ADT treatment or post orchiectomy: • Castrate serum testosterone levels: AND • Biochemical progression defined as Three (3) prostate-specific antigen (PSA) rises at least 1 week apart, with the last PSA greater than 2ng/mL; and 4. Patient is at high risk for developing metastatic disease based on a Prostate-specific antigen doubling time (PSADT) of less than or equal to 10 months during continuous ADT. 5. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2. Approval Duration: 1 year Exclusion Criteria: 1. The patient received prior chemotherapy for the treatment of prostate cancer, unless it was in the adjuvant or neoadjuvant setting. 2. The patient has previously experienced disease progression on apalutamide or darolutamide used for prostate cancer. 3. The patient has risk factors for seizures. 307 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) Approved Dosage: 160mg administered orally once daily Notes: 1. The Ministry will fund only one second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, or enzalutamide) in patients with nmCRPC. 2. Patients who have progressed on enzalutamide in nmCRPC will not be eligible for enzalutamide in metastatic castration resistant prostate cancer (mCRPC). 3. Requests for enzalutamide in patients who have initiated another ARI therapy in the nmCRPC setting and who have not experienced disease progression will be considered on a case-by-case basis. Renewal Criteria: Renewals will be considered in patients without evidence of radiographic disease progression or unacceptable toxicity while on enzalutamide therapy. Approval Duration: 1 year 308 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Initiation criteria for metastatic castration resistant prostate cancer (mCRPC): For the treatment of metastatic castration resistant prostate cancer (mCRPC) in patients meeting the following criteria: 1. Enzalutamide is used in combination with androgen deprivation therapy (ADT)1; AND 2. Metastatic lesions detected on a bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI); AND 3. Patient has castration resistant disease based on meeting the following indicia observed while on continuous ADT treatment or post orchiectomy: 4. Castrate serum testosterone levels; AND 5. Biochemical progression defined as three (3) prostate-specific antigen (PSA) rises at least 1 week apart, with the last PSA greater than 2ng/mL AND/OR radiographic progression of new or pre-existing disease as determined by the detection of 2 or more lesions on bone scan or presence of new soft tissue lesions by RECIST criteria; AND 6. Patient has progressed on a docetaxel-based chemotherapy OR Patient is using enzalutamide pre-docetaxel for metastatic castration resistant prostate cancer and has not previously experienced disease progression on enzalutamide or another second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide,) used for prostate cancer OR Patient is using enzalutamide pre-docetaxel for mCRPC and has not previously experienced disease progression on abiraterone used in mCRPC sequenced immediately prior to enzalutamide; AND 7. Patient has good performance status defined as an Eastern Cooperative Oncology Group (ECOG) Performance status less than or equal to 2. 1ADT is not required for patients with bilateral orchiectomy Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) ARAT- An androgen receptor axis targeted therapy (e.g. abiraterone, apalutamide, darolutamide, enzalutamide) 309 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Notes: 1. Patients who have progressed on treatment with second generation androgen receptor inhibitors (e.g. apalutamide, enzalutamide, darolutamide) used in prior stages of prostate cancer will not be eligible for enzalutamide in the metastatic castration resistant setting. 2. Patients treated with apalutamide or darolutamide as part of a clinical trial may be eligible for enzalutamide and will be considered on a case-by-case basis. 3. Requests for enzalutamide in patients who initiated abiraterone therapy and who have not had disease progression while on abiraterone will be considered on a case-by- case basis. Exclusion criteria: (Patients meeting any of the following will not be funded) 1. The patient has risk factors for seizures; 2. Enzalutamide will not be funded as combination therapy with another androgen receptor axis targeted therapy or cabazitaxel. Renewals: Renewals will be considered in patients who have not experienced disease progression while on enzalutamide therapy. Approved Dosage for Initials and Renewals:160 mg administered orally once daily. Duration of initial and renewal approvals: 1 year 310  EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 305, record 183, corpus 2025-01-01; name match only, not an eligibility decision

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Reddy-Enzalutamide · DIN 02558424 Manufacturer: Dr. Reddy's Laboratories Inc.; listing date 2026-05-29 Health Canada: Marketed since 2026-03-30 · brand REDDY-ENZALUTAMIDE · ATC L02BB04 ENZALUTAMIDE · form Capsule · route Oral · ingredients ENZALUTAMIDE 40 MG · company Dr reddy's laboratories ltd · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02558424). DIN 02558424: Reddy-Enzalutamide Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 100000224; group id 156; item number 0267; lccId None; manufacturer id DRR Source form: Cap; strength: 40mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $7.2989; ministry $7.2989 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02558424 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106167

Interchangeable products

Apo-Enzalutamide · DIN 02562677 · $7.2989 Auro-Enzalutamide · DIN 02494736 · $7.2989 Jamp Enzalutamide · DIN 02515229 · $7.2989 Xtandi · DIN 02407329 · $7.2989

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02558424

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Updated: December 1, 2021 Initiation criteria for metastatic castration sensitive prostate cancer (mCSPC): For the treatment metastatic castration sensitive prostate cancer (mCSPC) in patients who meet all of the following criteria: 1. Enzalutamide is used in combination with androgen deprivation therapy (ADT)1; AND 2. Metastatic lesions detected on technetium-99m bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI); AND 3. Castration sensitive as defined by the patient being treatment naïve to an ADT OR ADT initiated within the prior 6 months before start of therapy with enzalutamide OR ADT used in the neoadjuvant or adjuvant setting where the patient has been off treatment for 12 months or more prior to start of enzalutamide; AND 4. Has not experienced disease progression with another an androgen receptor axis targeted therapy (ARAT) for castration sensitive prostate cancer; AND 5. Patient has good performance status. 1ADT is not required for patients with bilateral orchiectomy Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) ARAT- An androgen receptor axis targeted therapy (e.g. abiraterone, apalutamide, darolutamide, enzalutamide) The following baseline levels are to be provided with the initial application; i) Number of metastatic lesions on bone scan and in soft tissues ii) Testosterone level iii) Baseline (pre-treatment) PSA level iv) Pre-treatment Gleason score (optional) 305 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Notes: 1. Patients who have previously progressed on a second-generation androgen receptor inhibitor (e.g. apalutamide, enzalutamide, darolutamide) for prostate cancer will not be eligible for enzalutamide in mCSPC. The Ministry will fund only one of enzalutamide or apalutamide in patients with mCSPC. 2. Patients treated with apalutamide or darolutamide as part of a clinical trial may be eligible for enzalutamide and will be considered on a case-by-case basis. 3. Patients who progress on treatment with enzalutamide or apalutamide mCSPC will not be eligible for enzalutamide in the metastatic castration resistant setting. 4. Patients who are currently on a treatment regimen with an androgen receptor axis targeted therapy (e.g. abiraterone or a second-generation androgen receptor inhibitor) for prostate cancer, must meet the initiation criteria if they wish to switch to publicly funded enzalutamide for mCSPC. 5. Time limited funding consideration will be provided on a case-by case basis for those patients who are using docetaxel in combination with ADT as long as there has been no progression and the treatment regimen has not been used for more than 6 months. Approved Dosage: 160 mg administered orally once daily. Renewal Criteria: Renewals will be considered in patients until disease progression (i.e. PSA elevation in addition to radiographic disease progression, or PSA progression in addition to clinical symptoms associated with cancer progression), development of castration resistant disease, or experiencing unacceptable toxicity while on enzalutamide. Exclusion Criteria: (Patients meeting any of the following will not be funded.) 1. Patients who have previously experienced disease progression on enzalutamide or another ARI used in the setting of prostate cancer. 2. Patients who have risk factors for seizures 3. Enzalutamide will not be funded as combination therapy with another androgen receptor axis targeted therapy. Approved Dosage for Initials and Renewals:160 mg administered orally once daily. Duration of initial and renewal approvals: 1 year 306 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Initiation Criteria for high risk non-metastatic castration resistant prostate cancer (nmCRPC): For the treatment of high risk non-metastatic castration resistant prostate cancer (nmCRPC) in patients who meet all the following criteria: 1. Patient using Xtandi in combination with androgen deprivation therapy (ADT); AND 2. Has no detectable distant metastases as determined by CT, MRI, or technetium-99m bone scan; AND 3. Patient has castration resistant disease based on meeting all the following indicia observed while on continuous ADT treatment or post orchiectomy: • Castrate serum testosterone levels: AND • Biochemical progression defined as Three (3) prostate-specific antigen (PSA) rises at least 1 week apart, with the last PSA greater than 2ng/mL; and 4. Patient is at high risk for developing metastatic disease based on a Prostate-specific antigen doubling time (PSADT) of less than or equal to 10 months during continuous ADT. 5. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2. Approval Duration: 1 year Exclusion Criteria: 1. The patient received prior chemotherapy for the treatment of prostate cancer, unless it was in the adjuvant or neoadjuvant setting. 2. The patient has previously experienced disease progression on apalutamide or darolutamide used for prostate cancer. 3. The patient has risk factors for seizures. 307 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) Approved Dosage: 160mg administered orally once daily Notes: 1. The Ministry will fund only one second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, or enzalutamide) in patients with nmCRPC. 2. Patients who have progressed on enzalutamide in nmCRPC will not be eligible for enzalutamide in metastatic castration resistant prostate cancer (mCRPC). 3. Requests for enzalutamide in patients who have initiated another ARI therapy in the nmCRPC setting and who have not experienced disease progression will be considered on a case-by-case basis. Renewal Criteria: Renewals will be considered in patients without evidence of radiographic disease progression or unacceptable toxicity while on enzalutamide therapy. Approval Duration: 1 year 308 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Initiation criteria for metastatic castration resistant prostate cancer (mCRPC): For the treatment of metastatic castration resistant prostate cancer (mCRPC) in patients meeting the following criteria: 1. Enzalutamide is used in combination with androgen deprivation therapy (ADT)1; AND 2. Metastatic lesions detected on a bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI); AND 3. Patient has castration resistant disease based on meeting the following indicia observed while on continuous ADT treatment or post orchiectomy: 4. Castrate serum testosterone levels; AND 5. Biochemical progression defined as three (3) prostate-specific antigen (PSA) rises at least 1 week apart, with the last PSA greater than 2ng/mL AND/OR radiographic progression of new or pre-existing disease as determined by the detection of 2 or more lesions on bone scan or presence of new soft tissue lesions by RECIST criteria; AND 6. Patient has progressed on a docetaxel-based chemotherapy OR Patient is using enzalutamide pre-docetaxel for metastatic castration resistant prostate cancer and has not previously experienced disease progression on enzalutamide or another second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide,) used for prostate cancer OR Patient is using enzalutamide pre-docetaxel for mCRPC and has not previously experienced disease progression on abiraterone used in mCRPC sequenced immediately prior to enzalutamide; AND 7. Patient has good performance status defined as an Eastern Cooperative Oncology Group (ECOG) Performance status less than or equal to 2. 1ADT is not required for patients with bilateral orchiectomy Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) ARAT- An androgen receptor axis targeted therapy (e.g. abiraterone, apalutamide, darolutamide, enzalutamide) 309 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Notes: 1. Patients who have progressed on treatment with second generation androgen receptor inhibitors (e.g. apalutamide, enzalutamide, darolutamide) used in prior stages of prostate cancer will not be eligible for enzalutamide in the metastatic castration resistant setting. 2. Patients treated with apalutamide or darolutamide as part of a clinical trial may be eligible for enzalutamide and will be considered on a case-by-case basis. 3. Requests for enzalutamide in patients who initiated abiraterone therapy and who have not had disease progression while on abiraterone will be considered on a case-by- case basis. Exclusion criteria: (Patients meeting any of the following will not be funded) 1. The patient has risk factors for seizures; 2. Enzalutamide will not be funded as combination therapy with another androgen receptor axis targeted therapy or cabazitaxel. Renewals: Renewals will be considered in patients who have not experienced disease progression while on enzalutamide therapy. Approved Dosage for Initials and Renewals:160 mg administered orally once daily. Duration of initial and renewal approvals: 1 year 310  EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 305, record 183, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Xtandi · DIN 02407329 Manufacturer: Astellas Pharma Canada Inc.; listing date 2026-03-31 Health Canada: Marketed since 2013-06-07 · brand XTANDI · ATC L02BB04 ENZALUTAMIDE · form Capsule · route Oral · ingredients ENZALUTAMIDE 40 MG · company Astellas pharma canada inc · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02407329). DIN 02407329: Xtandi Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 100000224; group id 156; item number 0267; lccId None; manufacturer id ASE Source form: Cap; strength: 40mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $29.1954; ministry $7.2989 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02407329 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89203

Interchangeable products

Apo-Enzalutamide · DIN 02562677 · $7.2989 Auro-Enzalutamide · DIN 02494736 · $7.2989 Jamp Enzalutamide · DIN 02515229 · $7.2989 Reddy-Enzalutamide · DIN 02558424 · $7.2989

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02407329

Shortage record checked 2026-09-13T08:10:21.292534+00:00